Clearside Biomedical Inc.

01/12/2021 | Press release | Distributed by Public on 01/12/2021 06:11

Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD